10:28:27 EST Thu 05 Mar 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Cipher Pharmaceuticals Inc
Symbol CPH
Shares Issued 25,281,181
Close 2026-03-04 C$ 14.86
Market Cap C$ 375,678,350
Recent Sedar+ Documents

ORIGINAL: Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call

2026-03-04 18:02 ET - News Release

Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call

Canada NewsWire

MISSISSAUGA, ON, March 4, 2026 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the fourth quarter and fiscal 2025 after the market close on Thursday, March 12, 2026. The Company will also hold a conference call on Friday, March 13, 2026 at 8:30am ET to discuss the results and corporate developments.

CONFERENCE CALL DETAILS

DATE:                                                                    Friday, March 13, 2026

TIME:                                                                     8:30 a.m. ET

DIAL-IN NUMBER:                                                416-945-7677 or 888-699-1199

REPLAY:                                                               289-819-1450 or 888-660-6345 Code: 29916#

                                                                              Expires: March 20, 2026

WEBCAST:                                                           https://app.webinar.net/G7lE687Woew

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.

SOURCE Cipher Pharmaceuticals Inc.

Cision View original content: http://www.newswire.ca/en/releases/archive/March2026/04/c0312.html

Contact:

For further information: Graham Farrell, Investor Relations - Cipher Pharmaceuticals, ir@cipherpharma.com, 416-842-9003

© 2026 Canjex Publishing Ltd. All rights reserved.